Olumiant (Baricitinib)

Baricitinib, the active ingredient in Olumiant, is a Janus kinase (JAK) inhibitor presented as a / for oral use. It modulates immune responses and is indicated for certain inflammatory conditions in adults. GNH USA supplies Olumiant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olumiant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olumiant acts through the JAK‑STAT pathway to address immune‑mediated diseases of the musculoskeletal system and skin.

- Rheumatoid arthritis: reduces pain and joint damage by decreasing inflammatory activity. - Psoriatic arthritis: improves joint symptoms and skin lesions. - Atopic atopy or eczema (AD): helps control moderate to the most severe forms of the disease. - Severe COVID‑19 hospital treatment in adults requiring oxygen support or vent … -  …  

Bar  ...